• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

    3/8/22 6:16:21 AM ET
    $NVS
    $PFE
    $VYGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVS alert in real time by email

    License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets

    Novartis agreement marks second recent major transaction to leverage Voyager's TRACER technology following October 2021 Pfizer agreement

    Strengthened leadership with appointment of Al Sandrock, Jr., M.D., Ph.D., to Board of Directors and Board Executive Committee, promotion of Robin Swartz to chief operating officer

    Cash runway extended into 2024 with $84 million aggregate upfront payments from Novartis and Pfizer transactions

    Conference call and webcast today at 8:30 a.m. ET

    CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today reported fourth quarter and full year 2021 financial and operating results.

    "We're extremely pleased with the value created by our TRACER™ capsid discovery platform, evidenced by the two major license option agreements with Novartis and Pfizer for target-specific access to our highly differentiated capsids, which affords us the opportunity to expand the impact of our technology through external program development by our partners. The potential of our novel TRACER capsids to improve transduction in target tissues and to minimize off target toxicities associated with conventional AAV delivery may enable a new wave of gene therapies to treat serious diseases," said Michael Higgins, interim CEO of Voyager. "We've also made important additions to our leadership team with Al Sandrock joining our Board and its Executive Committee, and the promotion of Robin Swartz to chief operating officer. We continue to leverage our proprietary AAV capsids to progress our pipeline and look forward to sharing new preclinical data from select programs and our TRACER platform at a medical conference this spring."

    Target-Specific License Option Agreement with Novartis Expands Applications of TRACER Capsids

    • Voyager today announced a license option agreement with Novartis AG (NYSE:NVS) through which Novartis may exercise options to license novel AAV capsids generated from Voyager's RNA-driven TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform for potential use with three undisclosed CNS targets and options to access capsids for two additional targets to be agreed on in the future, subject to availability. These targets are distinct from those being explored in Voyager's internal pipeline and other licensing agreements. Voyager retains global rights to its TRACER discovery platform and all capsids arising from it, subject to certain obligations under its agreement with Pfizer, as detailed below.
    • Voyager will receive $54 million up front and is entitled to receive up to $37.5 million in exercise fees for three initial CNS targets, exercisable by Novartis within 12 months of signing. In addition, Novartis may elect to evaluate capsids for up to two additional targets, to be agreed upon in the future, subject to availability, for $18 million upon selection of each target, and a $12.5 million exercise fee for selection of a capsid for each target. Voyager is also eligible to earn up to $1.5 billion in total development, regulatory, and commercial milestones for products utilizing Voyager-licensed capsids, as well as mid- to high-single-digit tiered royalties based on net sales of Novartis products incorporating the licensed capsids.

    Transgene-Specific License Option Agreement with Pfizer Supports CNS and Cardiac Applications for TRACER

    • In October, Voyager and Pfizer Inc. (NYSE:PFE) announced a license option agreement through which Pfizer may exercise options to license AAV capsids generated from the TRACER platform. Under the terms of the agreement, Pfizer received target-specific access to Voyager's TRACER capsids for one CNS and one cardiovascular target and the right to exercise options to license capsids for exclusive use in Pfizer's development of AAV gene therapies for each target. Voyager retains global rights to all TRACER capsids for use with other targets and to all other applications of its TRACER technology.
    • Voyager received $30 million upfront and is entitled to receive up to $20 million in exercise fees in aggregate for two options exercisable by Pfizer within 12 months of signing, and is eligible to earn up to $580 million in total development, regulatory, and commercial milestones, as well as mid- to high-single-digit tiered royalties based on net sales of Pfizer products incorporating the licensed capsids.

    Additional Data from Evolving TRACER AAV9 and AAV5 Capsid Portfolio Planned for Spring Medical Conference

    • Voyager continues to perform screening campaigns with its TRACER capsid discovery platform to identify additional proprietary AAV9- and AAV5-derived capsids and to refine capsids already identified to target multiple tissue and cell types for use in gene therapies to treat a broad range of diseases. Numerous promising capsids have been identified and developed from these screens, which are undergoing testing across multiple non-human primate (NHP) and rodent species to evaluate their clinical translatability.
    • Voyager previously presented data on a set of AAV9-derived TRACER capsids from its first campaign that demonstrated robust delivery across the blood-brain barrier and widespread CNS transduction in NHPs, compared to conventional AAV9 delivery, when dosed intravenously. In addition, another AAV9-derived TRACER capsid displayed strong cardiac transduction and significant dorsal root ganglia detargeting in NHPs, which may help avoid dose-related toxicities associated with AAV9 delivery.
    • Voyager has identified a new array of TRACER AAV9 and AAV5 variants that have demonstrated improved CNS targeting in both NHPs and rodents with certain AAV TRACER capsids showing a preferential tropism for glial cells, which may enable more effective targeting of relevant cell types for certain CNS diseases. AAV5 capsids have been shown to have a low prevalence of preexisting neutralizing antibodies in the general population and significant manufacturing advantages over conventional AAV9. In addition, some of these variants have demonstrated cross-species translatability across primates and rodents.
    • Voyager plans to present preclinical data on the performance of these TRACER capsids in NHP and mouse models at a spring medical conference.

    Positive Preclinical Data from Vectorized Anti-HER2 Antibody Program Highlights Advancement of Rich Early-Stage Pipeline

    • Voyager continues to advance its preclinical programs powered by its TRACER capsids. The Company believes these capsids may enable new, best-in-class gene therapy programs with systemic IV delivery with lower risk of dose-limiting toxicities. Our pipeline includes gene replacement programs for spinal muscular atrophy, diseases linked to GBA1 mutations (including Parkinson's disease, Lewy body dementia, and Gaucher disease), gene knockdown or silencing programs for SOD1 ALS and Huntington's disease, and vectorized antibody programs for HER2+ brain metastases and diseases associated with pathological tau (including Alzheimer's disease, frontal-temporal dementia, and progressive supranuclear palsy). Voyager plans to present further preclinical data from select programs at a spring medical conference.
    • In November, the Company presented positive preclinical data demonstrating that IV dosing of a novel TRACER AAV vector encoding an anti-HER2 antibody payload prevented tumor growth in mouse models of HER2+ brain metastases. This innovative, intravenously delivered vectorized antibody approach is designed to activate the innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in the CNS. In preclinical studies, widespread transduction of brain tissue was achieved, effectuating expression of HER2-directed antibodies for extended periods, resulting in substantially reduced tumor growth in multiple orthotopic xenograft models.

    Key Leadership Appointments Add to Deep R&D and Operational Experience

    • In February, Voyager announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D., to its Board of Directors and a newly-formed Executive Committee of the Board consisting of Dr. Sandrock, Mr. Higgins, and Glenn Pierce, M.D., Ph.D., Voyager's interim chief scientific officer. Dr. Sandrock is working work with Voyager leadership to help shape future strategies leveraging the Company's TRACER™ platform and therapeutic programs, and to expand its external collaborations with scientific leaders and industry partners. Dr. Sandrock joined Voyager following a prolific career in biopharmaceutical drug development.
    • The Company also recently announced the promotion of Robin Swartz to chief operating officer. Ms. Swartz joined Voyager in 2021 following a 25-year career with Genzyme and Sanofi Genzyme where she held a number of leadership positions, including Senior Vice President of U.S. and Global Business Operations, Senior Vice President U.S. Rare Disease Patient and Product Services, and Senior Director Finance.

    Fourth Quarter and Full Year 2021 Financial Results

    • Collaboration Revenues: Voyager had collaboration revenue of $28.1 million for the fourth quarter of 2021, compared to $6.5 million for the same period in 2020. The increase in collaboration revenue was largely due to a change in estimate related to our collaboration with Neurocrine Biosciences. For the year ended December 31, 2021, collaboration revenue was $37.4 million, compared to $171.1 million for the same period of 2020. The decrease in collaboration revenue is largely due to $105.2 million of revenue related to the AbbVie collaborations that was recognized upon the termination of the collaborations during 2020.
    • Net Loss: Net income was $5.7 million for the fourth quarter of 2021, compared to a net loss of $15.9 million for the same period of 2020. Net income was higher driven by the recognition of revenue related to our collaboration with Neurocrine Biosciences. Net loss was $71.2 million for the year ended December 31, 2021, compared to net income of $36.7 million for the same period of 2020. Voyager had net income for 2020 driven primarily by revenue related to the AbbVie collaborations which were terminated during 2020.
    • R&D Expenses: Research and development expenses were $14.0 million for the fourth quarter of 2021, compared to $22.0 million for the same period in 2020. For the year ended December 31, 2021, R&D expenses were $73.8 million, compared to $108.8 million for the same period of 2020. The decrease in R&D expenses was related to employee-related expenses driven by a reduction in headcount as well as lower external costs primarily for clinical development and manufacturing.
    • G&A Expenses: General and administrative expenses were $8.4 million for the fourth quarter of 2021, compared to $8.3 million for the same period in 2020. For the year ended December 31, 2021, G&A expenses were $37.2 million, compared to $35.0 million for the same period of 2020. The increase in G&A expenses was primarily related to employee-related severance expenses in connection with a reduction-in-force commenced in the third quarter of 2021 and facility costs.
    • Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2021 were $132.5 million. This cash position does not include the $54 million upfront payment Voyager is entitled to receive from Novartis as part of the Novartis license option agreement announced on March 8, 2022.

    Financial Guidance

    • Voyager expects that its cash, cash equivalents, and marketable securities inclusive of upfront payments anticipated to be received under the Novartis license option agreement will be sufficient to meet Voyager's planned operating expenses and capital expenditure requirements into 2024.

    Participation in Upcoming Investor Event

    • Cowen 42nd Annual Health Care Conference, corporate panel discussion, Mar. 9, 2022, 12:50 p.m. ET.

    Conference Call

    The Voyager Therapeutics leadership team will host a conference call and webcast today at 8:30 a.m. ET to provide and discuss the fourth quarter and full year 2021 financial and operating results and the Novartis license option agreement. To access the call, please dial (877) 851-3834 (domestic) or (631) 291-4595 (international) and ask for the Voyager Therapeutics earnings call. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

    About the TRACER™ AAV Capsid Discovery Platform

    Voyager's TRACER™ capsid discovery platform is a broadly applicable, RNA-based functional screening platform that allows for rapid in vivo evolution of AAV9- and AAV5-derived capsids with enhanced tropisms and cell- and tissue-specific transduction properties in multiple species, including non-human primates (NHPs). Initial data from the first of many libraries screened in NHPs demonstrated the proprietary capsid variants effectively penetrated the blood-brain barrier and achieved widespread biodistribution and transduction of multiple regions of the brain. Separate results have demonstrated the ability of certain capsids to transduce cardiac muscle and to de-target the dorsal root ganglia. Voyager is proceeding with additional capsid campaigns derived from AAV9, AAV5, and other capsid serotypes to identify novel AAV vectors optimized for specific therapeutic applications.

    About Voyager Therapeutics

    Voyager Therapeutics (NASDAQ:VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from the Company's TRACER discovery platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas. voyagertherapeutics.com        LinkedIn        Twitter

    Forward-Looking Statements

    This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "undoubtedly," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements.

    For example, all statements Voyager makes regarding Voyager's ability to continue to identify and develop proprietary capsids from its TRACER capsid discovery platform with increased transgene expression, increased blood-brain barrier penetration and increased biodistribution compared to conventional AAV9 and AAV5 capsids; Voyager's ability to utilize its novel proprietary capsids in its own product development programs; Voyager's ability to attract parties to license its novel proprietary capsids or to participate with Voyager in research and development collaborations utilizing its novel proprietary capsid; Voyager's ability to advance its AAV-based gene therapy programs; Voyager's ability to perform its obligations under its respective license option agreements with Novartis and Pfizer; Voyager's entitlement to receive upfront, option exercise, milestone and royalty-based fees from Novartis and Pfizer under the respective license option agreements; Voyager's ability to maintain its current partnerships and collaborations and to enter into new partnerships or collaborations; Voyager's ability to continue to advance and to receive regulatory approvals for product candidates under development in Voyager's pipeline; Voyager's anticipated financial results, including the receipt by Voyager of revenues or reimbursement payments from collaboration partners; and Voyager's ability to generate sufficient cash resources to enable it to continue to identify and develop proprietary capsids from its TRACER capsid discovery platform are forward looking.

    All forward-looking statements are based on estimates and assumptions by Voyager's management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the severity and length of the COVID-19 health crisis, the imposition of governmental controls and guidance addressing the COVID health crisis, and the financial and human resources available to Voyager to manage the COVID-19 health crisis; the continued development of various technology platforms, including Voyager's TRACER platform; the development by third parties of capsid identification platforms that may be competitive to Voyager's TRACER capsid discovery platform; Voyager's scientific approach and general development progress; Voyager's ability to attract and retain talented contractors and employees to continue the development of the TRACER capsid discovery platform and the identification of proprietary capsids; Voyager's ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform and the capsids identified by the platform; the response of the FDA and other regulators to Voyager's regulatory submissions and communications; the ability to attract and retain talented contractors and employees, including key scientists and business leaders; the ability to create and protect intellectual property; Voyager's ability to perform its obligations under its license option agreements and its counterparties' respective abilities to perform their obligations under such agreements; the sufficiency of cash resources; the possibility or the timing of the exercise of development, commercialization, license and other options under the Pfizer and Novartis license option agreements and other collaborations; the ability of Voyager to negotiate and complete licensing or collaboration agreements on terms acceptable to Voyager and third parties; and the availability or commercial potential of Voyager's product candidates.

    These statements are also subject to a number of material risks and uncertainties that are described in Voyager's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.



    Selected Financial Information

    ($-amounts in thousands, except per share data)

    (Unaudited)

                  
                  
      Three Months Ended  Year Ended
      December 31,  December 31, 
    Statement of Operations Items: 2021 2020  2021  2020
    Collaboration revenue $28,073 $6,537  $37,415   171,128
    Operating expenses:            
    Research and development  14,020  21,996   73,787   108,753
    General and administrative  8,351  8,270   37,246   34,991
    Total operating expenses  22,371  30,266   111,033   143,744
    Operating income (loss)  5,702  (23,729)  (73,618)  27,384
    Total other income  6  7,802   2,421   9,357
    Net income (loss) $5,708 $(15,927) $(71,197) $36,741
                 
    Net income (loss) per share, basic $0.15 $(0.43) $(1.89) $0.99
    Net income (loss) per share, diluted  0.15  (0.43)  (1.89)  0.98
                 
    Weighted-average common shares outstanding, basic  37,804,372  37,290,259   37,668,947   37,132,447
    Weighted-average common shares outstanding, diluted  37,804,372  37,290,259   37,668,947   37,348,514



           
      December 31, 
    Selected Balance Sheet Items 2021 2020
    Cash, cash equivalents, and marketable securities $132,539 $174,782
    Total assets $193,855 $261,584
    Accounts payable and accrued expenses $11,524 $14,839
    Deferred revenue $42,096 $43,817
    Total stockholders' equity $95,055 $154,320


    Contacts
    Investors
    [email protected]
    
    Andrew Funderburk
    [email protected]
    
    Media
    Scott Santiamo
    [email protected]  

    Primary Logo

    Get the next $NVS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NVS
    $PFE
    $VYGR

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Novartis AG
    $NVS
    2/13/2025Buy → Neutral
    UBS
    Novartis AG
    $NVS
    2/12/2025Underweight
    Morgan Stanley
    Novartis AG
    $NVS
    2/4/2025Hold → Buy
    Deutsche Bank
    Voyager Therapeutics Inc.
    $VYGR
    1/10/2025Overweight
    Cantor Fitzgerald
    Pfizer Inc.
    $PFE
    12/10/2024$29.00Neutral
    BofA Securities
    Novartis AG
    $NVS
    12/4/2024Hold → Reduce
    HSBC Securities
    Voyager Therapeutics Inc.
    $VYGR
    12/2/2024$12.00Buy
    Citigroup
    More analyst ratings

    $NVS
    $PFE
    $VYGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Pfizer with a new price target

      Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

      4/22/25 8:03:45 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novartis AG downgraded by UBS

      UBS downgraded Novartis AG from Buy to Neutral

      2/13/25 8:48:14 AM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Novartis AG

      Morgan Stanley initiated coverage of Novartis AG with a rating of Underweight

      2/12/25 7:07:04 AM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    $PFE
    $VYGR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)

      The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1EAST HANOVER, N.J., July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx was evaluated in combination with a 26-week steroid taper and compared to placebo plus a 52-week steroid taper. Cosentyx did not demonstrate a statistically significant improvement in sustained remission at Week 52 com

      7/3/25 1:25:00 AM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors

      Study demonstrates superiority, showing both statistically significant and clinically meaningful reduction in annualized bleeding rate with a generally well-tolerated safety profile compared to on-demand treatment in patients 12 years and older HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection that required minimal preparation Pfizer Inc. (NYSE:PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-we

      6/26/25 6:45:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Declares Third-Quarter 2025 Dividend

      Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery,

      6/25/25 5:30:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    $PFE
    $VYGR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 1, 2024 - FDA Roundup: November 1, 2024

      For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director

      11/1/24 3:18:19 PM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • October 25, 2024 - FDA Roundup: October 25, 2024

      For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

      10/25/24 2:48:21 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for HYMPAVZI issued to PFIZER INC

      Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

      10/15/24 2:57:27 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    $PFE
    $VYGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Taraporevala Cyrus

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:39:02 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith James C

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:38:59 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Narayen Shantanu

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:38:52 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    $PFE
    $VYGR
    Leadership Updates

    Live Leadership Updates

    See more
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate

      Industry veteran in clinical development of oncology therapeutics, Dr. Jens Wurthner, PhD, joins as Chief Medical Officer Lead development candidate, FORX-428, a PARG inhibitor for solid tumors, maintains progress toward IND submission by mid-2025 FoRx Therapeutics AG, a Swiss-based company committed to discovering and developing innovative drugs targeting cancer-relevant DDR (DNA Damage Response) pathways, today announced that it has appointed Jens Würthner, MD PhD, as Chief Medical Officer. He is further strengthening FoRx Therapeutics' existing management team with CEO Tarig Bashir, CSO Frank Zenke, and Head of Chemistry Ulrich Lücking. Jens Würthner has 20+ years of clinical devel

      2/26/25 9:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components

    $NVS
    $PFE
    $VYGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      2/14/25 5:16:36 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      10/31/24 4:06:54 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      12/19/23 9:31:01 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    $PFE
    $VYGR
    SEC Filings

    See more
    • SEC Form 11-K filed by Pfizer Inc.

      11-K - PFIZER INC (0000078003) (Filer)

      6/16/25 4:12:32 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Pfizer Inc.

      11-K - PFIZER INC (0000078003) (Filer)

      6/16/25 4:07:31 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Voyager Therapeutics Inc.

      S-8 - Voyager Therapeutics, Inc. (0001640266) (Filer)

      6/9/25 4:07:18 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NVS
    $PFE
    $VYGR
    Financials

    Live finance-specific insights

    See more
    • Pfizer Declares Third-Quarter 2025 Dividend

      Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery,

      6/25/25 5:30:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

      Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confere

      6/25/25 10:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

      Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.

      6/2/25 10:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVS
    $PFE
    $VYGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      11/14/24 6:13:11 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

      SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

      11/14/24 5:12:26 PM ET
      $VYGR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Novartis AG

      SC 13D/A - NOVARTIS AG (0001114448) (Filed by)

      10/17/24 4:01:28 PM ET
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care